IL2 (Interleukin 2)

The 5 mg/kg dose provided the most consistent benefit. These findings suggest that quercetin, particularly at 5 mg/kg, could serve as a potential adjunctive therapy to mitigate neurotoxic side effects associated with RT.

P2, N=25, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025

Here, we report the successful generation and expansion of TIL engineered with regulatable, membrane-bound IL15 (cytoTIL15™ cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2...Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

The fecal microbiota transplantation experiment further confirmed that the intestinal protective effect is likely mediated by OTM-altered gut microbiota and their metabolites. In summary, the replacement of ITM by OTM in chicken diets can minimize the negative impact on OSO induced intestinal damage by improving intestinal barrier function and alleviating inflammatory responses mediated by gut microbiota modulation and SCFA metabolism.

At the same time, A. muciniphila administration improves cognitive deficits, alleviates neuroinflammation and Aβ deposition via AhR/NF-κB/NLRP3 signaling pathway in APP/PS1 mice. In summary, our findings suggest A. muciniphila is a promising approach for preventing AD progression by microbiota-gut-brain axis.

The ThrivePath program provides a practical and accessible tool for survivors to manage their health following active treatment. By facilitating access to evidence-based resources and enabling direct communication with a care team, the program can help alleviate persistent symptoms, build confidence in self-management, and improve overall quality of life during the transition to survivorship.

An IL-10-based Trikine induced immune infiltration into poorly immunogenic tumors, showing efficacy in pre-clinical models of small cell lung cancer and pancreatic cancer. Trikines obviate the need for cell engineering to customize STAT signatures and may hold potential for immunotherapy.

FZP may promote the apoptosis of tumor cells by activating the endogenous Bax/Bcl-2/cleaved Caspase-3 apoptosis pathway, which is mediated by mitochondria. These findings revealed the potential of FZP in the treatment of HCC and provided more treatment options for patients.

The 2024 FDA approval of Lifileucel (Amtagvi), a commercially manufactured autologous TIL product, marks a key milestone in integrating advanced therapy medicinal products (ATMPs) into routine care for solid tumours...A nationally coordinated effort is required to harmonise clinical prioritisation strategies, maintain oversight by multidisciplinary specialist tumour boards, and consider investment in future-proof decentralised manufacturing capacity. Collaborations and peer support such as through the Advanced Therapy Treatment Centre (ATTC) Network will facilitate phased, experience-led rollout with equity-focused service design.

These findings nominate a lead B-cell maturation antigen (BCMA)-IL-2 CAR-E candidate with strong translational potential for clinical development and establish IL-2Rβγ as a key driver of CAR-E activity. The results also identify IL-2Rα as dispensable and provide a mechanistic framework for designing safer, IL-2Rα-sparing CAR-Es.

P1, N=8, Not yet recruiting, M.D. Anderson Cancer Center

He was treated with dexamethasone and etoposide, with rapid clinical improvement. This is a unique case of secondary hemophagocytic lymphohistiocytosis after a blood transfusion without other identifiable triggers, which has not yet been reported in the literature. This case underscores the importance of maintaining high clinical suspicion for hemophagocytic lymphohistiocytosis in adults with persistent fever and cytopenias, even in the absence of known triggers.